China Prostate Cancer Market Research Report: Size, Share, Trend Analysis By Types (Prostate Adenocarcinoma, Small Cell Carcinoma), By Component (Therapy, Diagnosis) and By End-User (Specialty Centers, Hospital & Clinics) - Growth Outlook & Industry Forecast 2025 To 2035
As per Market Research Future analysis, the China Prostate Cancer Market Size was estimated at 551.56 USD Million in 2024. The China prostate cancer market is projected to grow from 593.59 USD Million in 2025 to 1237.2 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 7.6% during the forecast period 2025 - 2035
The China prostate cancer market is experiencing robust growth driven by increasing awareness and advancements in treatment options.
| 2024 Market Size | 551.56 (USD Million) |
| 2035 Market Size | 1237.2 (USD Million) |
| CAGR (2025 - 2035) | 7.62% |
Astellas Pharma (JP), Bayer (DE), Bristol-Myers Squibb (US), Johnson & Johnson (US), Merck & Co. (US), Novartis (CH), Pfizer (US), Sanofi (FR), Ipsen (FR)
Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry
The prostate cancer market is experiencing notable transformations, driven by advancements in medical technology and increasing awareness among the population. In recent years, there has been a marked rise in the incidence of prostate cancer, prompting healthcare providers to enhance screening and diagnostic measures. This shift is largely attributed to the aging population and changing lifestyle factors, which have contributed to a higher prevalence of this disease. As a result, there is a growing demand for innovative treatment options, including targeted therapies and immunotherapies, which are becoming more accessible to patients. Moreover, the regulatory environment in China is evolving, with authorities implementing policies aimed at improving healthcare access and affordability. This has led to increased investment in research and development, fostering collaborations between pharmaceutical companies and research institutions. The focus on personalized medicine is also gaining traction, as treatments are tailored to individual patient profiles, potentially improving outcomes. Overall, the prostate cancer market is poised for growth, driven by technological advancements and a commitment to enhancing patient care.
The increasing awareness of prostate cancer among the population is leading to more frequent screenings and early detection. This trend is crucial as it allows for timely intervention, which can significantly improve patient outcomes. Public health campaigns are playing a vital role in educating men about the risks and symptoms associated with prostate cancer.
Innovative treatment modalities are emerging within the prostate cancer market, including targeted therapies and immunotherapies. These advancements are reshaping the therapeutic landscape, offering patients more effective and personalized treatment choices. The focus on precision medicine is likely to enhance treatment efficacy and minimize side effects.
The regulatory framework is becoming increasingly supportive of new therapies and technologies in the prostate cancer market. Government initiatives aimed at improving healthcare access are encouraging investment in research and development. This environment fosters collaboration between industry stakeholders, potentially accelerating the introduction of novel treatments.
The aging population in China is a critical driver for the prostate cancer market. As life expectancy rises, the number of elderly men, who are at a higher risk for prostate cancer, continues to grow. It is estimated that by 2030, the population aged 60 and above will reach approximately 487 million, representing about 35% of the total population. This demographic shift is likely to lead to an increase in prostate cancer diagnoses, thereby expanding the market. Furthermore, older individuals often require more advanced treatment options, which could further stimulate growth in the prostate cancer market. The healthcare system may need to adapt to accommodate this rising demand, potentially leading to increased investments in research and development for effective therapies.
China's rising healthcare expenditure is a substantial driver for the prostate cancer market. The government has been increasing its healthcare budget, aiming to provide better access to medical services and treatments. In 2025, healthcare spending is expected to reach approximately $1 trillion, reflecting a growth rate of around 7% annually. This increase in funding allows for more resources to be allocated towards cancer research, treatment facilities, and patient care. As a result, the prostate cancer market may benefit from enhanced treatment options and improved access to care, ultimately leading to better patient outcomes and increased market growth.
The expansion of treatment facilities in China is a notable driver for the prostate cancer market. As the demand for prostate cancer care increases, healthcare providers are establishing more specialized centers dedicated to cancer treatment. This expansion is supported by government initiatives aimed at improving healthcare infrastructure. By 2025, it is anticipated that the number of cancer treatment centers will increase by approximately 15%, enhancing access to care for patients. This growth in facilities not only improves patient access but also fosters an environment conducive to clinical trials and research, potentially leading to the development of new therapies in the prostate cancer market.
Public awareness campaigns regarding prostate cancer are becoming more prevalent in China, which is likely to drive the prostate cancer market. These initiatives aim to educate the population about the risks, symptoms, and importance of early detection. Increased awareness can lead to higher screening rates, resulting in earlier diagnoses and potentially better treatment outcomes. As more men become informed about prostate cancer, the demand for diagnostic and therapeutic services is expected to rise. This shift in public perception may encourage healthcare providers to invest more in prostate cancer-related services, further stimulating market growth.
Technological advancements in diagnostic tools are significantly impacting the prostate cancer market. Innovations such as MRI-guided biopsies and liquid biopsies are enhancing the accuracy of prostate cancer detection. These technologies not only improve early diagnosis but also reduce the need for invasive procedures, which can be a barrier to timely treatment. The market for diagnostic imaging in China is projected to grow at a CAGR of around 10% over the next five years. As healthcare providers increasingly adopt these advanced diagnostic methods, the prostate cancer market is likely to experience growth driven by improved patient outcomes and increased screening rates.
The China prostate cancer market is characterized by a significant market share by Prostatic Adenocarcinoma, which is currently the largest segment. This segment accounts for the majority of diagnosed cases, reflecting its prevalence in the population. In contrast, Small Cell Carcinoma, while smaller in total market share, is rapidly gaining ground as an emerging concern, showing an increasing number of cases attributed to its more aggressive nature. Growth trends indicate that the demand for targeted therapies and advanced diagnostics is on the rise. Factors contributing to the growth include increased awareness among healthcare providers, improved screening practices, and advancements in medical technology. This evolution in treatment options is expected to propel the Small Cell Carcinoma segment, while Prostatic Adenocarcinoma remains the foundational focus of cancer care strategies in the market.
Prostatic Adenocarcinoma (Dominant) vs. Small Cell Carcinoma (Emerging)
Prostatic Adenocarcinoma stands as the dominant type within the market, representing the majority of prostate cancer diagnoses due to its prevalence and well-established treatment protocols. Its management includes a variety of therapies ranging from hormonal treatments to surgical interventions, which are widely adopted. On the other hand, Small Cell Carcinoma is emerging as a significant concern due to its aggressive nature and lower survival rates. This segment is characterized by a smaller patient population but is becoming increasingly noteworthy in the context of clinical research and treatment innovation. The contrast in their treatment paradigms reflects the challenges in managing different types of prostate cancer.
In the China prostate cancer market, the component segment is predominantly led by Therapy, which holds a significant share due to its ongoing advancements in treatment methodologies and patient outcomes. Conversely, the Diagnosis segment, while smaller, is rapidly expanding as healthcare providers invest in innovative diagnostic technologies, driven by increasing awareness and the urgency of early detection. Growth trends within this segment are notable, with the Diagnosis component witnessing a surge owing to technological advancements such as AI and molecular diagnostics. This rapid growth is supported by government initiatives and rising healthcare expenditure, focusing on improving screening and early intervention strategies, making Diagnosis an emerging focus area in the prostate cancer landscape.
Therapy: Treatment (Dominant) vs. Diagnosis (Emerging)
In the China prostate cancer market, the Therapy segment, primarily focused on treatment methods such as hormone therapy, chemotherapy, and radiation, remains dominant. These therapies are well-established, boasting a wide acceptance among healthcare providers and patients alike. On the other hand, the Diagnosis segment is becoming increasingly important, especially with the rise of new diagnostic technologies like biomarker tests and imaging techniques. As a result, while Therapy remains the mainstay of treatment, the rapidly evolving Diagnosis segment is fostering a shift towards more proactive and personalized healthcare approaches, enhancing the overall treatment journey for patients.
In the China prostate cancer market, Specialty Centers hold a significant share compared to Hospitals & Clinics. These centers specialize in providing targeted treatments and advanced care for prostate cancer patients, contributing to a higher market presence. Hospitals & Clinics are essential support facilities that cater to a broader demographic, yet they lag behind Specialty Centers in market share. The growth trends for this segment are largely driven by the increasing number of prostate cancer diagnoses and advancements in treatment protocols. Specialty Centers are expanding their capabilities due to rising demand for specialized care, while Hospitals & Clinics are enhancing their services with improved technologies and treatment options. This environment positions both segments for growth, although Specialty Centers currently remain the key players.
Specialty Centers (Dominant) vs. Hospitals & Clinics (Emerging)
Specialty Centers are recognized as the dominant players in the treatment landscape of the China prostate cancer market. They focus on delivering comprehensive care, advanced diagnostic capabilities, and personalized treatment plans tailored to individual patient needs. These centers often house specialized medical professionals and cutting-edge technology, enhancing patient outcomes and driving patient loyalty. In contrast, Hospitals & Clinics are emerging as vital contributors, providing holistic care approaches and integrating newer technologies to improve prostate cancer management. They are adapting to changing patient needs by offering specialized services and expanding their treatment offerings, positioning themselves as accessible care options for the general population. As a result, they are gaining traction in the competitive landscape.
Get more detailed insights about China Prostate Cancer Market Request Free Sample
The prostate cancer market in China is characterized by a dynamic competitive landscape, driven by increasing incidence rates and a growing emphasis on early detection and innovative treatment options. Key players such as Astellas Pharma (Japan), Bayer (Germany), and Merck & Co. (US) are actively shaping the market through strategic initiatives that focus on research and development, partnerships, and regional expansion. Astellas Pharma (Japan) has positioned itself as a leader in advanced therapies, particularly with its focus on novel drug formulations that enhance patient outcomes. Bayer (Germany) emphasizes its commitment to precision medicine, leveraging its extensive research capabilities to develop targeted therapies that address specific patient needs. Merck & Co. (US) is also notable for its robust pipeline of immunotherapy options, which are increasingly becoming a cornerstone of prostate cancer treatment. In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance operational efficiency and reduce costs. The market structure appears moderately fragmented, with several players competing for market share while also collaborating on research initiatives. This collective influence of key players fosters a competitive environment that encourages innovation and rapid advancements in treatment modalities. In October 2025, Astellas Pharma (Japan) announced a strategic partnership with a leading Chinese biotechnology firm to co-develop a new prostate cancer therapy. This collaboration is expected to leverage local expertise and accelerate the development process, potentially leading to faster market entry and improved patient access. Such partnerships are indicative of a broader trend where companies seek to enhance their competitive edge through localized innovation. In September 2025, Bayer (Germany) launched a new digital health platform aimed at improving patient engagement and adherence to treatment protocols. This initiative reflects a growing recognition of the importance of digital tools in managing chronic conditions like prostate cancer. By integrating technology into patient care, Bayer is likely to enhance treatment outcomes and solidify its market position. In August 2025, Merck & Co. (US) received regulatory approval for a new immunotherapy that targets advanced prostate cancer. This approval not only expands Merck's product portfolio but also underscores the increasing reliance on immunotherapeutic approaches in oncology. The strategic importance of this development lies in its potential to address unmet medical needs and provide patients with more effective treatment options. As of November 2025, current competitive trends in the prostate cancer market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are playing a crucial role in shaping the landscape, as companies collaborate to enhance their research capabilities and market reach. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift suggests that companies that prioritize research and development, alongside strategic partnerships, will be better positioned to thrive in the evolving market.
The China Prostate Cancer Market has recently witnessed significant developments, particularly in the domain of new drug approvals and advancements in treatment options. As of September 2023, Eli Lilly and Company announced the launch of a new prostate cancer treatment that has shown promise in clinical trials, expanding the treatment landscape for patients in China.
Additionally, GSK and Roche are investing in Research and Development to enhance their prostate cancer therapies, aligning with China's growing focus on cancer treatment innovation. In terms of market growth, Amgen’s revenue from prostate cancer treatments increased by 20% in the last fiscal year, reflecting the rising demand for cancer care solutions in the region.
Notably, in June 2023, Astellas Pharma and Hisun Pharmaceuticals entered into a strategic licensing agreement aimed at co-developing prostate cancer therapies for the Chinese market, which could significantly bolster their footprints in the sector. Lastly, government initiatives in China are encouraging local production and innovation of cancer care, further driving competition among key players such as Pfizer Inc., Novartis AG, and Bayer AG, all of which are actively seeking to expand their market share in this high-potential field.
The Prostate cancer Market in China is projected to grow at a 7.62% CAGR from 2025 to 2035, driven by advancements in diagnostics, treatment options, and increasing awareness.
New opportunities lie in:
By 2035, the prostate cancer market is expected to achieve substantial growth and innovation.
| MARKET SIZE 2024 | 551.56(USD Million) |
| MARKET SIZE 2025 | 593.59(USD Million) |
| MARKET SIZE 2035 | 1237.2(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.62% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Astellas Pharma (JP), Bayer (DE), Bristol-Myers Squibb (US), Johnson & Johnson (US), Merck & Co. (US), Novartis (CH), Pfizer (US), Sanofi (FR), Ipsen (FR) |
| Segments Covered | Type, Component, End User |
| Key Market Opportunities | Advancements in precision medicine and targeted therapies enhance treatment options in the prostate cancer market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory adaptations in the prostate cancer market. |
| Countries Covered | China |
The overall market valuation was 551.56 $ Million in 2024.
The projected valuation for 2035 is 1237.2 $ Million.
The expected CAGR for the market during the forecast period 2025 - 2035 is 7.62 %.
The market segments include Prostatic Adenocarcinoma and Small Cell Carcinoma.
Prostatic Adenocarcinoma was valued at 400.0 - 850.0 $ Million, while Small Cell Carcinoma was valued at 151.56 - 387.2 $ Million.
The key components include Therapy and Diagnosis.
Therapy was valued at 386.56 - 850.0 $ Million, and Diagnosis was valued at 165.0 - 387.2 $ Million.
Key players include Astellas Pharma, Bayer, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., Novartis, Pfizer, Sanofi, and Ipsen.
End-user segments include Specialty Centers and Hospital & Clinics.
Specialty Centers were valued at 165.47 - 370.56 $ Million, while Hospital & Clinics were valued at 386.09 - 866.64 $ Million.
Kindly complete the form below to receive a free sample of this Report
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
“Thank you, this will be very helpful for OQS.”
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”
